Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arcutis Biotherapeutics Inc shares valued at $104,850 were sold by Edwards Larry Todd on May 19 ’25. At $14.07 per share, Edwards Larry Todd sold 7,451 shares. The insider’s holdings dropped to 183,104 shares worth approximately $2.5 million following the completion of this transaction.
Also, Heron Patrick J purchased 2,520 shares, netting a total of over 34,317 in proceeds. Following the buying of shares at $13.62 each, the insider now holds 17,494 shares.
Before that, Edwards Larry Todd had added 7,451 shares to its account. In a trade valued at $104,850, the Officer bought Arcutis Biotherapeutics Inc shares for $14.07 each.
As published in their initiating research note from H.C. Wainwright on December 30, 2024, Arcutis Biotherapeutics Inc [ARQT] has been a Buy and the price target has been revised to $19. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in late August. As of January 03, 2024, Mizuho has increased its “Neutral” rating to a “Buy” for ARQT. Earlier on October 26, 2023, Mizuho downgraded its rating. Their new recommendation was “a Neutral” for ARQT stock which previously was a “a Buy”.
Analyzing ARQT Stock Performance
During the last five days, there has been a surge of approximately 0.22%. Over the course of the year, Arcutis Biotherapeutics Inc shares have dropped approximately -1.94%. Shares of the company reached a 52-week high of $17.75 on 03/25/25 and a 52-week low of $11.13 on 02/11/25.
Support And Resistance Levels for Arcutis Biotherapeutics Inc (ARQT)
According to the 24-hour chart, there is a support level at 13.40, which, if violated, would cause prices to drop to 13.14. In the upper region, resistance lies at 14.01. The next price resistance is at 14.36. RSI (Relative Strength Index) is 45.13 on the 14-day chart, showing neutral technical sentiment.
